Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310480 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sebastian Neuber und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Cardiomyopathies, Heart Failure, Extracellular Vesicles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, DFG.
Abstract (Originalsprache)
Heart failure is the leading cause of morbidity and mortality and currently affects more than 60 million people worldwide. A key feature in the pathogenesis of almost all forms of heart failure is cardiac fibrosis, which is characterized by excessive accumulation of extracellular matrix components in the heart. Although cardiac fibrosis is beneficial in the short term after acute myocardial injury to preserve the structural and functional integrity of the heart, persistent cardiac fibrosis contributes to pathological cardiac remodeling, leading to mechanical and electrical dysfunction of the heart. Despite its high prevalence, standard therapies specifically targeting cardiac fibrosis are not yet available. Cell-based approaches have been extensively studied as potential treatments for cardiac fibrosis, but several challenges have been identified during clinical translation. The observation that extracellular vesicles (EVs) derived from stem and progenitor cells exhibit some of the therapeutic effects of the parent cells has paved the way to overcome limitations associated with cell therapy. However, to make EV-based products a reality, standardized methods for EV production, isolation, characterization, and storage must be established, along with concrete evidence of their safety and efficacy in clinical trials. This article discusses EVs as novel therapeutics for cardiac fibrosis from a translational perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), 13353 Berlin, Germany.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
- BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
- German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, 13353 Berlin, Germany.
- Institute for Regenerative Medicine, University of Zurich, 8044 Zurich, Switzerland.
ORCID-Profile: Sebastian Neuber
Förderung
- Deutsche Forschungsgemeinschaft
- DFG
Zitieren
APA
Neuber, S., Ermer, M. R., Emmert, M. Y., & Nazari-Shafti, T. Z. (2023). Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310480
Vancouver
Neuber S, Ermer MR, Emmert MY, Nazari-Shafti TZ. Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310480
BibTeX
@article{Neuber2023,
author = {Neuber, Sebastian and Ermer, Miriam R and Emmert, Maximilian Y and Nazari-Shafti, Timo Z},
title = {Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310480}
}
EUVIMED